Skip to main content

Advertisement

Table 2 Performance of algorithms using TLCs alone or in combination with Hb and BMI in predicting CD4 cell counts ≤ 350 cells/μL in the Home-Based AIDS Care project, Tororo, Uganda

From: Determining eligibility for antiretroviral therapy in resource-limited settings using total lymphocyte counts, hemoglobin and body mass index

TLC Lower threshold TLC Upper threshold Hb threshold BMI threshold Sensitivity for CD4 <350 Specificity for CD4 <350 accuracy sensitivity for CD4<200 False Positives N Qualifying For ART
A) CD4 alone     1.00 1.00 1.00 1.00 0 1230
B) TLC alone
1500     0.40 0.95 0.67    519
1750     0.59 0.85 0.67 0.69 0.11 801
2000     0.71 0.69 0.71 0.80 0.17 1043
*2250     0.81 0.54 0.73 0.88 0.21 1250
2500     0.88 0.41 0.73 0.93 0.24 1404
2750     0.92 0.28 0.72 0.96 0.27 1523
3000     0.95 0.21 0.71 0.97 0.28 1601
C) TLC combined with Hb and/or BMI
1750 2750 11   0.71 0.75 0.68 0.81 0.14 1017
1750 2750 12   0.78 0.62 0.73 0.86 0.18 1180
1750 2750   18 0.64 0.77 0.68 0.75 0.14 917
1750 2750 11 18 0.74 0.69 0.73 0.84 0.16 1087
*2000 3000 11   0.81 0.62 0.75 0.88 0.18 1212
2000 3000 12   0.85 0.51 0.74 0.94 0.21 1335
2000 3000   18 0.75 0.63 0.72 0.84 0.19 1138
**2000 3000 11 18 0.83 0.57 0.75 0.90 0.20 1268
1750 2500 11   0.69 0.76 0.72 0.79 0.14 989
1750 2500 12   0.79 0.61 0.73 0.84 0.20 1169
1750 2500 11 18 0.72 0.72 0.72 0.82 0.15 1045
2000 2750 11   0.79 0.62 0.74 0.86 0.18 1190
2000 2750   18 0.75 0.64 0.71 0.83 0.19 1128
2000 2750 11 18 0.81 0.57 0.74 0.89 0.20 1242
D) TLC combined with Hb and/or BMI for WHO stages I and II only
**2000 3000 11   0.80 0.62 0.74 0.93 0.19 1282
2000 3000 11 18 0.83 0.57 0.73 0.90 0.20 1328
E) TLC combined with Hb and/or BMI for men only
2000 3000 11   0.58 0.71 0.72 0.80 0.12  
2000 3000 12   0.76 0.63 0.73 0.84 0.14  
2000 3000 11 18 0.77 0.60 0.73 0.87 0.14  
**2000 3000 12 18 0.80 0.57 0.75 0.89 0.15  
  1. Models with the highest accuracy using TLC alone (*) and TLC and Hb +/- BMI (**)
  2. ‡ Includes offering ART to 333 subjects with WHO stage III disease of whom 46 had CD4 cell counts > 350 cells/μL.